Scilex Holding Company

1 CConfonfiidentdentiialal::FFororIInnttee rrnalnalSSCCIILELEXX PPhhararmmacaceuteutiiccalalssUUseseOnOn llyy11 ScilexHoldingCompanyInnovative Leader in Non-Opioid Pain TherapeuticsDecember2021 THISDOCUMENTCONTAINSPROPRIETARYINFORMATI ONT H ,NORTHEPROPRIETARYINFORMATIONCONTAINEDHE REIN,SHALLBEPUBLISHED,REPRODUCED,COPIED, DISCLOSEDORUSEDFORANYOTHERPURPOSE, Harbor Statements Forward-Looking StatementsCertain statements contained in this corporate presentation (this Presentation ), along with certain statements that may be made by management of ScilexHolding Company (together with its subsidiaries, Scilex ) orally in presenting this material, are or may be considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as estimate, expect, intend, believe, plan, anticipate, potential, projected and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition.

2 Scilexcautions that these statements are based upon the current beliefs and expectations of Scilex smanagement and are subject to significant risks, uncertainties and assumptions. Statements regarding future actions, future performance and/or future results including, without limitation, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA s or other regulatory review and/or approval and commercial launch and sales results (if any) of Scilex sformulations and products and regulatory filings related to the same, financial projections and targets, business strategy, plans and objectives for future operations, and statements regarding the proposed business combination (the Proposed Business Combination ) between Scilexand Vickers Vantage Corp. I (the SPAC ) may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

3 In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Presentation are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. ScilexScilexHoldingCompanyTHISDOCUMENTCO NTAINSPROPRIETARYINFORMATIONT H ,NORTHEPROPRIETARYINFORMATIONCONTAINEDHE REIN,SHALLBEPUBLISHED,REPRODUCED,COPIED, DISCLOSEDORUSEDFORANYOTHERPURPOSE, no obligation to update publicly or revise any forward-looking statements for any reason after the date of this Presentation or to conform these statements to actual results or to changes in Scilex and Market DataCertain data in this Presentation was obtained from various external sources, and neither Scilexnor its affiliates, advisers or representatives has verified such data with independent sources.

4 Accordingly, neither Scilexnor any of its affiliates, advisers or representatives makes any representations as to the accuracy or completeness of that data or undertakes any obligation to update such data after the date of this Presentation. Such data involves risks and uncertainties and is subject to change based on various factors. TrademarksThe trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Information and Where to Find ItThis Presentation references the Proposed Business Combination between Scilexand the SPAC. This Presentation does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

5 In connection with the transaction described herein, contingent upon execution of the proposed merger agreement for the business combination (the Merger Agreement ), the SPAC would file relevant materials with the SEC, including a registration statement on Form S-4, which will include a proxy statement/prospectus. ScilexHoldingCompanyTHISDOCUMENTCONTAINS PROPRIETARYINFORMATIONT H ,NORTHEPROPRIETARYINFORMATIONCONTAINEDHE REIN,SHALLBEPUBLISHED,REPRODUCED,COPIED, DISCLOSEDORUSEDFORANYOTHERPURPOSE, and security holders of the SPAC are urged to read these materials (including any amendments or supplements thereto) and any other relevant documents in connection with the transaction that the SPAC files with the SEC when, and if, they become available because they will contain important information about the SPAC, Scilexand the proposed preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other relevant materials in connection with the transaction (when and if they become available), and any other documents filed by the SPAC with the SEC, may be obtained free of charge at the SEC s website ( ).

6 The documents filed by the SPAC with the SEC also may be obtained free of charge upon written request to: Vickers Vantage Corp. I, 85 Broad Street, 16th Floor, New York, NY in the SolicitationIf the parties execute the proposed Merger Agreement, the SPAC and its directors and executive officers may be deemed participants in the solicitation of proxies from SPAC s shareholders with respect to the Proposed Business Combination. Information about the SPAC s directors and executive officers and a description of their interests in the SPAC will be included in the proxy statement/prospectus for the Proposed Business Combination and would be available at the SEC s website ( ). Additional information regarding the interests of such participants will be contained in the proxy statement/prospectus for the Proposed Business Combination when H ,NORTHEPROPRIETARYINFORMATIONCONTAINEDHE REIN,SHALLBEPUBLISHED,REPRODUCED,COPIED, DISCLOSEDORUSEDFORANYOTHERPURPOSE, its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of the SPAC in connection with the Proposed Business Combination.

7 Information about Scilex sdirectors and executive officers and information regarding their interests in the Proposed Business Combination will be included in the proxy statement/prospectus for the Proposed Business Combination when Presentation is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitationof an offer to buy the securities of the SPAC, Scilexor the combined Company , nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as )ScilexHoldingCorporateOverview2)ZTlido )SP-102(SEMDEXA)forLumbarRadicularPain/ Sciatica4)SP-103(3 XZTlido)forLowBackPain5)DBRLowDose naltrexone (LDN)forFibromyalgia6)CompanyS ummaryScilexHoldingCompanyScilexHoldingC ompanyConfidential: ForInternalSCILEX Pharmaceuticals UseOnly10 CorporateOverviewScilexHoldingCompanySci lexHoldingCompanyVickers StrengthsStrong deal structuring, investing and M&A experience within the fin-tech spaceSignificant private and public investment experienceHistory of working within highly regulated industries requiring vast and rigorous due diligence effortsNecessary experience in working with international governments and government regulatorsScilexLOIS cilexHolding Company ( Scilex ), a subsidiary of Sorrento Therapeutics, Inc.

8 (Nasdaq: SRNE), and Vickers Vantage Corp I (Nasdaq: VCKA) signed a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Scilexof approximately $ billion, subject to adjustment, with expected gross proceeds of up to $140 million ScilexBusiness Combination with Vickers Vantage Corp IVickers Vantage Corp. IIPO Overview:Gross Proceeds: $ MillionIPO Date: January 6, 2021 Sponsor: Vickers Venture PartnersAbout Vickers Venture PartnersFounded in 2005 Deep technology focused global VC$432 Million invested to-date across six funds(1)Gross Value across six funds circa $1 Billion(1)Global footprint with international transaction and diligence experience21 investment professionals across sectors and geographies, almost all with advanced degrees in their respective specialtiesNote: (1) As of 30 June (s)ExperienceJaisimShahCEO & President 25+ yearsof managementexperience in large Pharma and Biotech Leadcommercializationof multipleblockbustersRituxan , Abilify , Pegasys ,BuSpar , Tequin CEO, Semnur Pharma;CBO, Elevation;CBO, PDLBioPharma;VP,Bristol-Myers.

9 Director,RocheSureshKhemaniSVP,Commercia l 25+yearsof seniormanagementexperience in theindustry Seniormanagementpositionsat BMS,Chiron,PDLBioPharma, KnoppBioscience Multiple blockbuster product launch experiences in US and overseasDmitriLissin,MDSVP,ChiefMedicalO fficer 20+yearsin clinicaldevelopment inpain& CNSdiseases VPClinical,Xenoport;VP Clinical,DurectSteve LincolnInterim ChiefLegal and Compliance Officer 20+ yearsin industry, withexpertise in legal/compliance and international partnering SciclonePharma, Kosan Bio, SuperGen, PDL BioPharmaNajjamAsgharInterimChiefFinanci alOfficer 17+yearsfunctionsof Finance,AccountingandTax,instrumentalin severalacquisitions CFO,NuVasive,Inc.,PricewaterhouseCoopers HenryJi, PhDExecutiveChairman 25+yearsof experiencein thebiotechnologyandlife sciences industry Founder& CEO,Chair SorrentoTherapeutics& ScilexHoldingScilexExecutive Management TeamScilexHoldingCompanyPlatformProgramI NDP hase1 Phase2 Phase3 PivotalNDAA pprovedUpcoming MilestonesNon-Opioid Pain ManagementZTlido (PostherpeticNeuralgia-PHN)Launched US October2018SP-102 (SEMDEXA) (Lumbar Radicular / SciaticaPain)Pivotal Phase3 trial enrollment completed & toplin e resu lts inDecember (3X)(LowBackPain)Initiating Phase2 in January 2022SP-104,Delayed Burst Low dose naltrexone (Fibromyalgia)Initiating Phase1 in Q4-2021 Best-in-Class Non-Opioid Pain TherapeuticsScilexHoldingCompanyScilexHo ldingCompany2021 ScilexBusiness UpdateIn April 2021, Scilexreceived a supplemental new drug application (sNDA)

10 Approval from the FDA for ZTlidoto expand the label for use in water stress conditionsIn 2020, ZTlidohad US net sales ~$27MM, which represents a ~35% growth rate YoY 2019 Scilexis currently projecting strong sales growth in 2021 ZTlidoin the US. Discussions ongoing for registering/partnering ex-US rights to ZTlidoand other pipeline programsSP-102 (SEMDEXA) pivotal Phase 3 trial completed enrollment in July 2021, with highly significant positive topline results released in December 2021. Fast Track status granted by FDAE xecuted a LOI/term sheet for business combination with a SPAC (Vickers Vantage Corp. I) for a pre-transaction equity value of approximately $ billion, subject to adjustment, and expected total proceeds of $140 millionSP-103 (3x formulation of ZTlido) Phase 2 trial acute back pain on track to commence in January 2022SP-104 (Delayed Burst Low dose naltrexone ) Phase 1 clinical trials began in Q4-2021 ScilexHoldingCompany15,000-20,000 Target PhysiciansConsist of a Mix of Health Care Specialists,Focusin High VolumeClinicsSource: Campbell Alliance Market Research; Clinical Guidelines: Lumbar Disk Herniation with Radiculopathy.